FDA Approves Pritelivir for Herpes Simplex Lesions
The agency greenlit the medication on October 9, 2026, to treat patients with immunocompromised immune systems.
Updated on Oct. 26, 2026 in Diseases — General
Live Poll
Should the government fast-track approval for new treatments targeting rare or refractory infections?
On October 9, 2026, the FDA approved pritelivir to treat lesions caused by the herpes simplex virus. This marks the first approved treatment for refractory mucocutaneous infections in immunocompromised patients.
Why it matters
Before this approval, there were no designated treatments for refractory mucocutaneous herpes simplex infections in immunocompromised patients. The new medication provides a necessary option for patients struggling to manage these lesions.
A safety population of 227 patients reported treatment-emergent adverse events in 29.1% of cases. Drug-related serious adverse events occurred in 2.2% of the study population.
The players
FDA
The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety and efficacy of human drugs and biological products.
Asahi Kasei Therapeutics
Asahi Kasei Therapeutics is a pharmaceutical company that provided funding for the clinical study of pritelivir.
The details
Patients receive a 400-mg loading dose of oral pritelivir followed by 100 mg daily for up to 28 days, with the option to extend treatment to 42 days. Funding for the study was provided by Asahi Kasei Therapeutics.
Timeline
October 9, 2026: The FDA approved pritelivir to treat herpes simplex virus lesions.
October 26, 2026: Program findings were presented at IDWeek 2026.
Health Landscape
This development follows the standard regulatory path established for the FDA drug approval process for orphan or specialized indications. The approval signals a shift toward addressing unmet needs for immunocompromised patient populations.
Immunocompromised patients suffering from refractory lesions may now have access to a specific treatment option after consulting with their healthcare providers. Patients should discuss potential side effects, which occurred in roughly 8.4% of study participants as drug-related events, with their doctors.
The takeaway
The approval of pritelivir offers a targeted therapeutic approach for a previously difficult-to-treat patient population. Healthcare providers can now evaluate this medication for patients who have not responded to traditional therapies for mucocutaneous herpes.
Further reading
Learn more about advancements in medical treatments within the Diseases — General section.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Should the government fast-track approval for new treatments targeting rare or refractory infections?
